Article Text

Download PDFPDF
Authors’ response: Central toxic keratopathy: a clinical case series
  1. José Marí Cotino1,2,
  2. Mayerling M Suriano3,
  3. Rosario De La Cruz Aguiló1,
  4. Jorge Vila-Arteaga1,4
  1. 1 Ophthalmology, Hospital Clínico Universitario de Valencia, Valencia, Valencia, Spain
  2. 2 Ophthalmology, Hospital Quirón de Valencia, Valencia, Valencia, Spain
  3. 3 Ophthalmology, Hospital Universitario de La Ribera, Valencia, Valencia, Spain
  4. 4 Ophthalmology, Clínica Dr. Vila, Valencia, Valencia, Spain
  1. Correspondence to Dr Mayerling M Suriano, Ophthalmology Service, Hospital Clínico Universitario de Valencia, AV Blasco Ibáñez, 17, Alzira, Valencia 46010, Spain; mayerlingsuriano{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read the letter written by Garcia-Gonzalez and Teus about our article ‘Central toxic keratopathy: a clinical case series’.

We would like to state that in all our cases (which is the second largest series), spontaneous recovery of the hyperopic shift and visual acuity was seen.

CTK is an entity already recognised by most ophthalmologists with this name. This term was first coined by Sonmez and Maloney in 2007.1 However, this entity has received various names, such as central necrosis lamellar imflamation,2 central lamellar keratitis,3 central flap necrosis,4 and the most recent, keratinocyte-induced corneal micro-oedema (KME).5 ,6

As Garcia-Gonzalez and colleagues …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.